Zacks Research Issues Pessimistic Forecast for CRL Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of Charles River Laboratories International in a research report issued to clients and investors on Wednesday, March 12th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $2.08 per share for the quarter, down from their prior forecast of $3.10. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International’s Q2 2025 earnings at $2.38 EPS, Q3 2025 earnings at $2.51 EPS, Q4 2025 earnings at $2.58 EPS, FY2025 earnings at $9.55 EPS, Q1 2026 earnings at $2.46 EPS, Q2 2026 earnings at $2.66 EPS, Q3 2026 earnings at $2.71 EPS, Q4 2026 earnings at $2.78 EPS and FY2026 earnings at $10.60 EPS.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm’s revenue for the quarter was down 1.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.46 EPS.

Several other research firms also recently commented on CRL. Robert W. Baird cut their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a report on Thursday, February 20th. Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective for the company in a report on Monday, March 3rd. The Goldman Sachs Group cut their price target on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Bank of America cut their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Finally, William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $191.31.

Charles River Laboratories International Trading Up 1.1 %

NYSE CRL opened at $177.02 on Monday. The company has a market cap of $9.05 billion, a PE ratio of 1,180.13, a PEG ratio of 4.54 and a beta of 1.45. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. Charles River Laboratories International has a 12 month low of $150.79 and a 12 month high of $274.77. The stock has a 50 day moving average of $167.21 and a 200-day moving average of $184.18.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC increased its position in shares of Charles River Laboratories International by 3.2% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,970 shares of the medical research company’s stock worth $1,102,000 after purchasing an additional 187 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Charles River Laboratories International in the fourth quarter valued at about $3,583,000. Jefferies Financial Group Inc. grew its position in Charles River Laboratories International by 226.7% in the fourth quarter. Jefferies Financial Group Inc. now owns 17,802 shares of the medical research company’s stock valued at $3,286,000 after acquiring an additional 12,353 shares during the last quarter. Mackenzie Financial Corp grew its position in Charles River Laboratories International by 0.6% in the fourth quarter. Mackenzie Financial Corp now owns 977,073 shares of the medical research company’s stock valued at $180,368,000 after acquiring an additional 5,805 shares during the last quarter. Finally, Forum Financial Management LP grew its position in Charles River Laboratories International by 30.3% in the fourth quarter. Forum Financial Management LP now owns 1,565 shares of the medical research company’s stock valued at $289,000 after acquiring an additional 364 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Insiders Place Their Bets

In related news, CEO James C. Foster purchased 6,075 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The shares were bought at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).